| アブストラクト | INTRODUCTION: Emerging off-label medical uses of ketamine for the treatment of persistent conditions such as depression and chronic pain often require repeated administration. Cases reported by other countries suggest that long-term and repeated exposure to ketamine may be associated with several risks, including but not limited to hepatobiliary damage. OBJECTIVE: We aimed (1) to characterize the association between repeated administration of ketamine for off-label medical use and hepatobiliary events and (2) to describe recent trends in the use of ketamine across different clinical settings. METHODS: We conducted a retrospective case series analysis, utilizing reports identified from the US Food and Drug Administration Adverse Event Reporting System database as well as the medical literature. We included all cases reported through July 2018 describing both repeated exposure to ketamine in a hospital or ambulatory setting and a hepatobiliary adverse event. We excluded cases describing ketamine abuse. We identified adverse hepatobiliary events using the Medical Dictionary for Regulatory Activities (MedDRA((R))) and summarized various case characteristics including: patient demographics, route of ketamine administration, dose, time to onset of event, type of event, and pre-existing risk factors for hepatobiliary disease. To assess trends in the demand for ketamine, we used IQVIA, National Sales Perspectives to provide the nationally estimated number of vials sold for ketamine from the manufacturer to all US channels of distribution from 2013 through 2017. RESULTS: We identified 14 unique cases that met selection criteria with 21 hepatobiliary adverse events including liver enzyme elevation in all cases, biliary dilation with liver cirrhosis (n = 1), biliary dilation with cholangitis (n = 1), and pericholeductal fibrosis (n = 1). Most cases received ketamine for the treatment of complex regional pain syndrome or chronic pain. In cases with a reported time to onset, the majority of events occurred within 4 days. The nationally estimated number of ketamine vials sold in the USA from manufacturers to various channels of distribution increased from 1.2 million in 2013 to 2.1 million in 2017. CONCLUSIONS: We report an association between repeated or continuous administration of ketamine and hepatobiliary adverse events. Increased awareness among clinicians may mitigate these adverse outcomes, especially in the context of growing ketamine sales. |
|---|
| ジャーナル名 | Drug safety |
|---|
| Pubmed追加日 | 2021/10/27 |
|---|
| 投稿者 | Cotter, Samantha; Wong, Jennie; Gada, Neha; Gill, Rajdeep; Jones, S Christopher; Chai, Grace; Foster, Daniel; Avigan, Mark; Mundkur, Mallika |
|---|
| 組織名 | Affiliated with the Office of Surveillance and Epidemiology, Office of;Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, US;Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD, 20993,;USA. Samantha.Cotter@fda.hhs.gov.;USA.;Affiliated with the Office of New Drugs, Center for Drug Evaluation and Research,;US Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD,;20993, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34699023/ |
|---|
